Innoviva Long Term Debt 2006-2019 | INVA

Innoviva long term debt from 2006 to 2019. Long term debt can be defined as the sum of all long term debt fields.
Innoviva Annual Long Term Debt
(Millions of US $)
2019 $377
2018 $383
2017 $574
2016 $708
2015 $733
2014 $726
2013 $288
2012 $173
2011 $173
2010 $173
2009 $173
2008 $173
2007 $0
2006 $1
2005 $1
Innoviva Quarterly Long Term Debt
(Millions of US $)
2019-12-31 $377
2019-09-30 $389
2019-06-30 $388
2019-03-31 $386
2018-12-31 $383
2018-09-30 $381
2018-06-30 $487
2018-03-31 $485
2017-12-31 $574
2017-09-30 $578
2017-06-30 $639
2017-03-31 $702
2016-12-31 $708
2016-09-30 $719
2016-06-30 $722
2016-03-31 $735
2015-12-31 $733
2015-09-30 $744
2015-06-30 $738
2015-03-31 $732
2014-12-31 $726
2014-09-30 $705
2014-06-30 $738
2014-03-31 $288
2013-12-31 $288
2013-09-30 $288
2013-06-30 $460
2013-03-31 $460
2012-12-31 $173
2012-09-30 $173
2012-06-30 $173
2012-03-31 $173
2011-12-31 $173
2011-09-30 $173
2011-06-30 $173
2011-03-31 $173
2010-12-31 $173
2010-09-30 $173
2010-06-30 $173
2010-03-31 $173
2009-12-31 $173
2009-09-30 $173
2009-06-30 $173
2009-03-31 $173
2008-12-31 $173
2008-09-30 $173
2008-06-30 $173
2008-03-31 $173
2007-12-31 $0
2007-09-30 $0
2007-06-30 $0
2007-03-31 $1
2006-12-31 $1
2006-09-30 $1
2006-06-30 $1
2006-03-31 $1
2005-12-31 $1
2005-09-30 $1
2005-06-30 $1
2005-03-31 $2
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.228B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $351.030B 15.34
Roche Holding AG (RHHBY) Switzerland $285.240B 0.00
Merck (MRK) United States $194.963B 14.81
Novartis AG (NVS) Switzerland $191.594B 15.95
Pfizer (PFE) United States $182.351B 11.14
Novo Nordisk (NVO) Denmark $140.446B 24.11
Eli Lilly (LLY) United States $136.072B 23.54
Bristol-Myers Squibb (BMY) United States $124.637B 11.82
AstraZeneca (AZN) United Kingdom $114.843B 24.72
AbbVie (ABBV) United States $110.942B 8.40
Sanofi (SNY) France $108.955B 12.95
GlaxoSmithKline (GSK) United Kingdom $94.072B 11.93
Bayer (BAYRY) Germany $53.827B 7.76
H Lundbeck (HLUYY) Denmark $6.010B 10.44